Supernus to Host First Quarter 2021 Financial Results Conference Call Read more about Supernus to Host First Quarter 2021 Financial Results Conference Call
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD Read more about Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
Supernus to Present at Cowen Healthcare Conference Read more about Supernus to Present at Cowen Healthcare Conference
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results Read more about Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call Read more about Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA Read more about Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients Read more about Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference Read more about Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD Read more about Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
Supernus to Participate in Annual Piper Sandler Healthcare Conference Read more about Supernus to Participate in Annual Piper Sandler Healthcare Conference